dc.contributor.author |
Cardona Zorrilla, Andrés Felipe |
dc.contributor.author |
Rojas, Leonardo |
dc.contributor.author |
Wills, Beatriz |
dc.contributor.author |
Arrieta, Oscar |
dc.contributor.author |
Carranza, Hernán |
dc.contributor.author |
Vargas, Carlos |
dc.contributor.author |
Otero, Jorge |
dc.contributor.author |
Cuello, Mauricio |
dc.contributor.author |
Corrales, Luis |
dc.contributor.author |
Martín, Claudio |
dc.contributor.author |
Ortiz, Carlos |
dc.contributor.author |
Franco Cirera, Sandra |
dc.contributor.author |
Rosell, Rafael |
dc.date |
2016 |
dc.identifier |
https://ddd.uab.cat/record/174676 |
dc.identifier |
urn:10.1371/journal.pone.0154293 |
dc.identifier |
urn:oai:ddd.uab.cat:174676 |
dc.identifier |
urn:pmid:27191954 |
dc.identifier |
urn:scopus_id:84971264245 |
dc.identifier |
urn:wos_id:000376286100015 |
dc.identifier |
urn:altmetric_id:7744622 |
dc.identifier |
urn:pmc-uid:4871516 |
dc.identifier |
urn:pmcid:PMC4871516 |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:4871516 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
PloS one ; Vol. 11 Núm. 5 (May 2016) |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/4.0/ |
dc.subject |
Pulmons Càncer Tractament |
dc.subject |
Pemetrexed |
dc.subject |
Carboplatin |
dc.subject |
Bevacizumab |
dc.title |
Pemetrexed/Carboplatin/Bevacizumab followed by maintenance Pemetrexed/Bevacizumab in hispanic patients with non-squamous non-small cell lung cancer: outcomes according to Thymidylate Synthase Expression |
dc.type |
Article |
dc.description.abstract |
Altres ajuts: FICMAC/017-2014 |
dc.description.abstract |
Objective: To evaluate the efficacy and safety of pemetrexed, carboplatin and bevacizumab (PCB) followed by maintenance therapy with pemetrexed and bevacizumab (PB) in chemotherapy-naïve patients with stage IV non-squamous non-small cell lung cancer (NSCLC) through the influence of thymidylate synthase (TS) protein and mRNA expression on several outcomes. The primary endpoints were the overall response rate (ORR), progression-free survival (PFS) and overall survival (OS). Methods: A cohort of 144 patients were administered pemetrexed (500 mg/m2), carboplatin (AUC, 5.0 mg/ml/min) and bevacizumab (7.5 mg/kg) intravenously every three weeks for up to four cycles. Maintenance PB was administered until disease progression or unacceptable toxicity. Results: One hundred forty-four Colombian patients with a median follow-up of 13.8 months and a median number of 6 maintenance cycles (range, 1-32) were assessed. The ORR among the patients was 66% (95% CI, 47% to 79%). The median PFS and (OS) rates were 7.9 months (95% CI, 5.9-10.0 months) and 21.4 months (95% CI, 18.3 to 24.4 months), respectively. We documented grade 3/4 hematologic toxicities, including anemia (14%), neutropenia (8%), and thrombocytopenia (16%). The identified grade 3/4 non-hematologic toxicities were proteinuria (2%), venous thrombosis (4%), fatigue (11%), infection (6%), nephrotoxicity (2%), and sensory neuropathy (4%). No grade >3 hemorrhagic events or hypertension cases were reported. OS was significantly higher in patients with the lowest TS mRNA levels [median, 29.6 months (95% CI, 26.2-32.9)] compared with those in patients with higher levels [median, 9.3 months (95% CI, 6.6-12.0); p = 0.0001]. TS expression (mRNA levels or protein expression) did not influence the treatment response. Conclusion: Overall, PCB followed by maintenance pemetrexed and bevacizumab was effective and tolerable in Hispanic patients with non-squamous NSCLC. This regimen was associated with acceptable toxicity and prolonged OS, particularly in patients with low TS expression. We found a role for Ki67 and TS expression as prognostic factors. |